tiprankstipranks
Trending News
More News >
Virax Biolabs Group Ltd. Class A (VRAX)
NASDAQ:VRAX
US Market
Advertisement

Virax Biolabs Group Ltd. Class A (VRAX) Price & Analysis

Compare
108 Followers

VRAX Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Market ExpansionManagement expects to expand ImmuneSelect distribution channels into the U.S markets.
Research CollaborationThe company announced that a multi-center longitudinal observational study had started enrolling patients in the UK, conducted in collaboration with the UK’s National Health Service.
Bears Say
Development StageVirax Biolabs is a UK-based development-stage in vitro diagnostics company focused on T cell diagnostics.

Financials

Options Prices

Currently, No data available
---

Ownership Overview

0.01%0.31%99.67%
Insiders
0.31% Other Institutional Investors
99.67% Public Companies and
Individual Investors

VRAX FAQ

What was Virax Biolabs Group Ltd. Class A’s price range in the past 12 months?
Virax Biolabs Group Ltd. Class A lowest stock price was $0.74 and its highest was $9.00 in the past 12 months.
    What is Virax Biolabs Group Ltd. Class A’s market cap?
    Currently, no data Available
    When is Virax Biolabs Group Ltd. Class A’s upcoming earnings report date?
    The company’s upcoming earnings report date is not yet available.
    How were Virax Biolabs Group Ltd. Class A’s earnings last quarter?
    Currently, no data Available
    Is Virax Biolabs Group Ltd. Class A overvalued?
    According to Wall Street analysts Virax Biolabs Group Ltd. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Virax Biolabs Group Ltd. Class A pay dividends?
      Virax Biolabs Group Ltd. Class A does not currently pay dividends.
      What is Virax Biolabs Group Ltd. Class A’s EPS estimate?
      Virax Biolabs Group Ltd. Class A’s EPS estimate for its next earnings report is not yet available.
      How many shares outstanding does Virax Biolabs Group Ltd. Class A have?
      Virax Biolabs Group Ltd. Class A has 4,341,956 shares outstanding.
        What happened to Virax Biolabs Group Ltd. Class A’s price movement after its last earnings report?
        Currently, no data Available
        Which hedge fund is a major shareholder of Virax Biolabs Group Ltd. Class A?
        Currently, no hedge funds are holding shares in VRAX

        Company Description

        Virax Biolabs Group Ltd. Class A

        Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
        Similar Stocks
        Company
        Price & Change
        Follow
        Biodexa Pharmaceuticals
        Salarius Pharmaceuticals
        Quoin Pharmaceuticals
        GRI Bio
        Protagenic Therapeutics
        Popular Stocks
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis